DOCSLIB.ORG

United States Patent (19) 11) 4,250,169 Hosoi Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11) 4,250,169 Hosoi Et Al United States Patent (19) 11) 4,250,169 Hosoi et al. (45) Feb. 10, 1981 54 METHOD OF PRODUCING ANTIBIOTICS 56) References Cited SUPPOSITORIES U.S. PATENT DOCUMENTS 2,854,378 9/1958 Buckwalter .......................... 424/271 75 Inventors: Kaoru Hosoi; Tadamasa Ikeda, both 2,931,798 4/1960 Umezawa et al. ................... 424/8 of Yokohama; Takemi Nakayoshi, 2,975,099 3/1961 Goyan et al. ... ... 424/18 Kawasaki; Akira Okada, Zushi, all of Japan 3,325,472 6/1967 Sackler ................................. 424/227 FOREIGN PATENT DOCUMENTS 73) Assignee: Meiji Seika Kaisha Ltd., Japan 1915191 10/1969 Fed. Rep. of Germany ........... 424/114 OTHER PUBLICATIONS (21) Appl. No.: 45,967 The Merck Index, 9th Ed. (1976), #2969. 22 Filed: Jun. 6, 1979 Primary Examiner-allen J. Robinson Attorney, Agent, or Firm-John J. McGlew Related U.S. Application Data 57 ABSTRACT 63 Continuation of Ser. No. 870,524, Jan. 18, 1978, aban A method of producing aminoglycoside antibiotics in doned. the form of suppositories which comprises dispersing an aminoglycoside antibiotic substance or its non-toxic salts in an oleaginous or aqueous base to which at least 30 Foreign Application Priority Data . a nonionic surface-active agent and/or an anionic sur Jan. 21, 1977 (JP) Japan .................................... 52-4854 face active agent are added and forming said substances with said base into a pharmaceutically safe and effective 51) Int, C. ...................... A61K 31/70; A61K 31/71 suppository for using in living animals and humans, e.g. 52 U.S. C. .................................... 424/181; 424/180; in infants. 424/0IG, 15 58 Field of Search ................ 424/180, 181, DIG. 15 1 Claim, No Drawings 4,250,169 1. 2 antibiotics prepared in the form of suppositories. More METHOD OF PRODUCING ANTIBIOTICS particularly, the inventors of the present invention dis SUPPOSITORIES persed an aminoglycoside antibiotic substance or its salt in an oily or aqueous base mixed with at least a nonionic This is a continuation of application Ser, No. 870,524 surface-active agent and/or anionic surface-active filed Jan. 18, 1978 and now abandoned. agent, and thereby enabled the rectal absorption of the antibiotic and succeeded in achieving the effective BACKGROUND OF THE INVENTION blood concentration thereof. In this case, the dosage The present invention relates to a method of produc may be made in form of suppositories specified in the ing aminoglycoside antibiotics suppositories. 10 Japanese Pharmacopoeia or in the form of a paste. In The systemic administration of medicine is usually the latter case, the paste-like medicine is injected into performed either orally or by injection. Aminoglyco the rectum. side antibiotics, when administered orally, are very poorly absorbed through digestive tracts and as a result DESCRIPTION OF SPECIFICEMBODIMENT OF the concentration thereof in the blood cannot reach an 15 THE INVENTION effective therapeutic level. Therefore, these antibiotics According to the present invention, there is provided are administered only by injection at present. Inciden a method of producing aminoglycoside antibiotic sup tally, the capsules and granules of these antibiotics positories which comprises dispersing an aminoglyco which are now on sale as medicines for oral administra side antibiotic substance or a non-toxic salt thereof in an tion are intended not to be absorbed through digestive 20 oily or aqueous base to which at least a nonionic sur tracts but to control bacterial infections inside the diges face-active agent and/or an anionic surface-active agent tive tracts. are added, and forming said substance with said bore Aminoglycoside antibiotics, including streptomycin, into a pharmaceutically acceptable antibiotic supposi kanamycin, bekanamycin, ribostamycin, gentamycin, tory. amikacin, tobramycin, dibekacin and others, consist of a 25 The aminoglycoside antibiotics that can be used in group of antibiotics which are substances very effective the present invention include streptomycin, kanamycin, in the treatment of bacterial infections, since they act bekanamycin, ribostamycin, gentamycin, amikacin, to extensively on Gram-positive bacteria, Gram-negative bramycin, dibekacin, etc., and their sulfates, hydrochlo bacteria, acid-fast bacteria, etc. At present, however, rides and other non-toxic salts which can maintain in the systemic administration of these antibiotics is neces 30 herent "basic" properties when dissolved into solutions, sarily performed by injection, especially by intramuscu The oily or oleaginous bases used in the present in lar injection for the reasons mentioned above. Thus, it vention include those usually used for producing sup has been heretofore considered totally impossible to positories: for instance, oils and fats such as sesame oil, achieve the effective absorption of such aminoglycoside olive oil, soybean oil, cacao butter, coconut oil, beef antibiotics by any of the usual administration methods 35 tallow and lard; those obtained by modifying the above except for injection. Also, there has been no report mentioned oils and fats through hydrogenation, fatty known to the present inventors as yet on a procedure by acid exchange or by other processes; mineral oils such which these aminoglycoside antibiotics were success as vaseline and paraffin; and higher fatty acids such as fully absorbed in the body by any of the usual methods stearic acid and oleic acid. These oils, fats, mineral oils except for injection. and fatty acids may be used singly or in combination. Recently, however, it was revealed that intramuscu The aqueous bases that can be used in the present lar injection especially for infants might cause muscular invention include polyoxyethylene glycol, propylene atrophy. Since then, it has been eagerly desired to estab glycol, glycerogelatin, etc., which may be used singly lish a safe systemic administration method especially for or in combination. infants, instead of injection. 45 As the nonionic surface-active agent in the present invention the following agents are useful, for instance, SUMMARY AND OBJECTS OF THE polyoxyethylene nonylphenyl ether (for instance, INVENTION “EMULGEN-903" and “EMULGEN-920' produced It is, therefore, an object of the present invention to by KAO ATRAS CO.,LTD., and “NIKKOL NP-10' provide a method of producing aminoglycoside antibi 50 produced by NIKKO CHEMICALS CO., LTD.), otics in the form of suppositories which make it possible polyoxyethylene alkyl ether (for instance, "Lauromac to achieve the effective absorption of aminoglycoside rogol' listed in the Pharmacopoeia, and "NIKKOL antibiotics without relying upon the disadvantageous BC-20' produced by NIKKO CHEMICALS CO., administration methods as have been mentioned above. LTD.), polyoxyethylene sorbitan fatty acid ester (for Suppositories for systemic administration have the 55 instance, "Polysorbate 80' listed in the Pharmacopoeia, following advantages, as is well known, and, therefore, and “NIKKOL TO-10" produced by NIKKO CHEM are very useful: they require no medical assistance when ICALS CO.,LTD.), and polyoxyethylene stearate (for administered, as in the case of injections; they can be instance, "Polyoxyl 40 stearate' listed in the Pharmaco easily administered even in case of emergency at night; poeia, and “NIKKOL MYS-40' produced by NIKKO they give no pain or local disturbance when adminis CHEMICALS CO.,LTD.). tered; they can be administered safely and easily even to As the anionic surface active agent in the present infants; they undergo no drug inactivation action by invention the following agents are useful for instance, gastric juices, unlike oral drugs, and they exert no irri sodium lauryl sulfate (for instance, "NIKKOL SLS' tant action on gastrointestinal tracts; they can be admin produced by NIKKO CHEMICALS CO. LTD.), so istered to patients to whom oral administration is impos 65 dium lauryl phosphate (for instance, "NIKKOL SLP sible; and they have other useful features. The inventors N” produced by NIKKO CHEMICALS, CO.,LTD.), of the present invention made efforts for many years to and alkyl-sulfo-succinate (for instance, "AEROSOL realize the effective rectal absorption of aminoglycoside OT” produced by ACC CO., LTD., and “NIKKOL 4,250,169 3 4. OTP-100" produced by NIKKO CHEMICALS CO., LTD.) EXAMPLE 3 The addition of the surface-active agent is preferably 10 g (in potency) of bekanamycin sulfate was added in the range of about about 2 to 10% by weight of the to a mixture containing 10 g of polyoxyethlene stearate suppository. 5 (“NIKKOL MYS-45’ produced by NIKKO CHEMI Although the addition of the above-mentined antibi CALS CO., LTD.) and 80 g of an aqueous base called otic substance is variable according to the desired thera "Macrogol 6000" (polyethylene glycol, listed in the peutic doses, it is generally 5 to 80% by weight. The Pharmacopoeia), and was fully dispersed therein while above-mentioned oleaginous or aqueous base can be being heated and mixed at 60° C. The product thus used in a desired amount to form suppositories 10 obtained was poured into individual suppository con Now the present invention will be hereinafter de tainers, 1.5 g for each; and then was naturally cooled to scribed in detail with reference to several examples: obtain desired suppositories. One of these suppositories was rectally administered to a rabbit (about 3 kg in EXAMPLE weight); then, blood samples were collected when the 10 g (in potency) of bekanamycin was added to a 15 following periods of time had elapsed after administra
Load more

Recommended publications
  • Pharmaceutical Applications Notebook
    Pharmaceutical Applications Notebook Antibiotics Table of Contents Index of Analytes .......................................................................................................................................................................3 Introduction to Pharmaceuticals ................................................................................................................................................4 UltiMate 3000 UHPLC+ Systems .............................................................................................................................................5 IC and RFIC Systems ................................................................................................................................................................6 MS Instruments .........................................................................................................................................................................7 Chromeleon 7 Chromatography Data System Software ..........................................................................................................8 Process Analytical Systems and Software ................................................................................................................................9 Automated Sample Preparation ..............................................................................................................................................10 Analysis of Antibiotics ...........................................................................................................................................................11
    [Show full text]
  • G Genito Urinary System and Sex Hormones
    WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
    [Show full text]
  • P147-Bioorgchem-Kanamycin Nucleotidyltransferase-1999.Pdf
    Bioorganic Chemistry 27, 395±408 (1999) Article ID bioo.1999.1144, available online at http://www.idealibrary.com on Kinetic Mechanism of Kanamycin Nucleotidyltransferase from Staphylococcus aureus1 Misty Chen-Goodspeed,* Janeen L. Vanhooke,² Hazel M. Holden,² and Frank M. Raushel*,2 *Department of Chemistry, Texas A&M University, College Station, Texas 77843; and ²Department of Biochemistry, Institute for Enzyme Research, University of Wisconsin, Madison, Wisconsin 53705 Received December 16, 1998 Kanamycin nucleotidyltransferase (KNTase) catalyzes the transfer of the adenyl group from MgATP to either the 4Ј or 4Љ-hydroxyl group of aminoglycoside antibiotics. The steady state kinetic parameters of the enzymatic reaction have been measured by initial velocity, product, and dead-end inhibition techniques. The kinetic mechanism is ordered where the antibiotic binds prior to MgATP and the modified antibiotic is the last product to be released. The effects of altering the relative solvent viscosity are consistent with the release of the products as the rate-limiting step. The pH profiles for Vmax and V/KATP show that a single ionizable group with apK of ϳ8.9 must be protonated for catalysis. The V/K profile for kanamycin as a function of pH is bell-shaped and indicates that one group must be protonated with a pK value of 8.5, while another group must be unprotonated with a pK value of 6.6. An analysis of the kinetic constants for 10 different aminoglycoside antibiotics and 5 nucleotide triphosphates indicates very little difference in the rate of catalysis or substrate binding among these substrates. ᭧ 1999 Academic Press Key Words: kanamycin nucleotidyltransferase; antibiotic modification.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No
    THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 732 , 370 B2 Jagesar ( 45 ) Date of Patent: Aug. 15, 2017 ( 54 ) METHOD FOR THE DETERMINATION OF ( 58 ) Field of Classification Search THE PRESENCE OF AN ANTIBIOTIC IN A None FLUID See application file for complete search history. (71 ) Applicant: DSM IP ASSETS B . V ., Heerlen (NL ) ( 56 ) References Cited ( 72 ) Inventor : Dhiredj Chandre Jagesar , Echt (NL ) U . S . PATENT DOCUMENTS 2007/ 0092929 A1* 4 / 2007 Dekker .. .. .. C12Q 1/ 18 ( 73 ) Assignee : DSM IP ASSETS B . V ., Heerlen (NL ) 435 / 32 ( * ) Notice : Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .C . 154 (b ) by 0 days . EP 0005891 A112 / 1979 EP 0285792 Al 10 / 1988 ( 21) Appl. No .: EP 0611001 AL 8 / 1994 14 /787 , 859 EP 1639122 A1 3 /2006 WO 2005005655 AL 1 / 2005 ( 22 ) PCT Filed : Apr. 30 , 2014 wo 2013057182 AL 4 /2013 ( 86 ) PCT No . : PCT/ EP2014 / 058778 OTHER PUBLICATIONS $ 371 (c ) ( 1 ) , ( 2 ) Date : Oct. 29 , 2015 International Search Report from corresponding PCT/ EP2014 / 058778 , mailed Jul . 23 , 2014 . Gilbertson et al. , “ Modified Microbiological Method for the Screen ( 87 ) PCT Pub . No . : WO2014 / 177597 ing of Antibiotics in Milk ” , 1995 , J. Dairy Sci , vol. 78 , PCT Pub . Date : Nov . 6 , 2014 XP27050235, pp . 1032 - 1038 . (65 ) Prior Publication Data * cited by examiner US 2016 / 0076071 A1 Mar . 17 , 2016 Primary Examiner — Kade Ariani ( 30 ) Foreign Application Priority Data (74 ) Attorney , Agent, or Firm - McBee Moore Woodward & Vanik IP , LLC ; Susan McBee ; Chester May 2 , 2013 (EP ) .
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • 1 Revealing SARS-Cov-2 Functional Druggability Through Multi-Target
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 May 2020 doi:10.20944/preprints202005.0199.v1 Revealing SARS-CoV-2 Functional Druggability Through Multi-Target Cadd Screening of Repurposable Drugs Yash Gupta1,2, Dawid Maciorowski1,3, Raman Mathur1, Catherine M Pearce1, David J. IIc1,3, Hamza Husein1,3, Ajay Bharti4, Daniel P. Becker3, Brijesh Rathi2,5, Steven B Bradfute6, Ravi Durvasula1,2, Prakasha Kempaiah1,2* 1 Loyola University Chicago Stritch School of Medicine, Chicago, IL, 60153, USA; 2 Department of Medicine, Loyola University Medical Center, Chicago, IL, 60153, USA; 3 Loyola University Chicago, Chicago, IL, USA; 4 Division of Infectious Diseases, Department of Medicine, University of California, San Diego, CA, 92093, USA, 5 Laboratory for Translational Chemistry and Drug Discovery, Hansraj College, University of Delhi, India; 6 Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. Number of Tables: 10; Number of Figures: 16 ABSTRACT: The emergence of SARS/MERS drug resistant COVID-19 with high transmission and mortality has recently been declared a deadly pandemic causing economic chaos and significant health problems. Like all coronaviruses, SARS-CoV-2 is a large virus that has many druggable components within its proteome. In this study, we focused on repurposing approved and investigational drugs by identifying potential drugs that are predicted to effectively inhibit critical enzymes within SARS-CoV-2. We shortlisted seven target proteins with enzymatic activities known to be essential at different stages of the virus life cycle. For virtual screening, the energy minimization of a crystal structure or modeled protein was carried out using Protein Preparation Wizard (Schrödinger LLC, 2020-1).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Determinants of Aminoglycoside-Binding Specificity for Rrna by Using Mass Spectrometry (16S RNA͞18S Rna͞fourier Transform Ion Cyclotron Resonance Ms͞aminoglycoside)
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10129–10133, August 1999 Biophysics Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry (16S RNA͞18S RNA͞Fourier transform ion cyclotron resonance MS͞aminoglycoside) RICHARD H. GRIFFEY*, STEVEN A. HOFSTADLER,KRISTIN A. SANNES-LOWERY,DAVID J. ECKER, AND STANLEY T. CROOKE Ibis Therapeutics, a Division of Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008 Communicated by Klaus Biemann, Massachusetts Institute of Technology, Cambridge, MA, July 7, 1999 (received for review May 25, 1999) ABSTRACT We have developed methods for studying the unique advantages for rapid characterization of RNA binding interactions between small molecules and RNA and have with aminoglycosides or any chemical or biological substrate. applied them to characterize the binding of three classes of Mixtures of compounds can be screened in parallel with a aminoglycoside antibiotics to ribosomal RNA subdomains. high-resolution Fourier transform ion cyclotron resonance High-resolution MS was used to quantitatively identify the (FT-ICR) mass spectrometer, because the exact molecular noncovalent binding interactions between mixtures of amino- mass of each ligand serves as a unique intrinsic label. Because glycosides and multiple RNA targets simultaneously. Signal ESI-MS measurements are performed from solutions of the overlap among RNA targets was avoided by the addition of RNA(s) and small molecules, the relative concentrations of the neutral mass tags that direct each RNA target to a unique components and buffers can be adjusted to determine binding region of the spectrum. In addition to determining binding constants over a broad range of conditions (13–15). The affinities, the locations of the binding sites on the RNAs were location of binding has been ascertained with ESI-MS͞MS identified from a protection pattern generated by fragmenting protection experiments performed selectively on ions from the ͞ the aminoglycoside RNA complex.
    [Show full text]
  • Bekanamycin | Medchemexpress
    Inhibitors Product Data Sheet Bekanamycin • Agonists Cat. No.: HY-B1174 CAS No.: 4696-76-8 Molecular Formula: C₁₈H₃₇N₅O₁₀ • Molecular Weight: 483.51 Screening Libraries Target: Bacterial; Antibiotic Pathway: Anti-infection Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro H2O : ≥ 100 mg/mL (206.82 mM) DMSO : 1 mg/mL (2.07 mM; ultrasonic and warming and heat to 80°C) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.0682 mL 10.3410 mL 20.6821 mL Stock Solutions 5 mM 0.4136 mL 2.0682 mL 4.1364 mL 10 mM 0.2068 mL 1.0341 mL 2.0682 mL Please refer to the solubility information to select the appropriate solvent. BIOLOGICAL ACTIVITY Description Bekanamycin (Kanamycin B) is an aminoglycoside antibiotic produced by Streptomyces kanamyceticus, against an array of Gram-positive and Gram-negative bacterial strain[1][2]. In Vitro Bekanamycin (Kanamycin B) is a precursor for semisynthetic antibiotics such as Arbekacin and Dibekacin and is generally extracted from the broth of S. kanamyceticus[2]. Bekanamycin (Kanamycin B) in a concentration-dependent fashion reduces reversibly the quantal content of the end-plate potentials while it has no observable effect on the configuration of the extracellularly recorded presynaptic action potential. The reduction in evoked transmitter release produced by Bekanamycin could be antagonized either by increasing the external calcium concentration or by drugs like the aminopyridines which are to greatly enhance transmitter release from motor nerve terminals.
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]